File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Loss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B

TitleLoss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis B
Authors
KeywordsEntecavir
Hepatitis
Hepatitis B surface antigen
Hepatitis B virus
Issue Date2010
PublisherBlackwell Publishing Ltd.
Citation
Journal Of Viral Hepatitis, 2010, v. 17 n. 1, p. 16-22 How to Cite?
AbstractThis retrospective analysis was conducted to describe the characteristics of nucleoside-naïve hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B, who achieved hepatitis B surface antigen (HBsAg) loss during entecavir or lamivudine therapy. HBeAg-positive adults with chronic hepatitis B, elevated serum alanine aminotransferase, and compensated liver disease were randomized to double-blind treatment for up to 96 weeks with entecavir 0.5 mgday or lamivudine 100 mgday. HBsAg and hepatitis B virus (HBV) DNA were measured at regular intervals during and off-treatment follow-up. Through a maximum duration of 96 weeks on-treatment and 24 weeks off-treatment, HBsAg loss was confirmed in 18354 (5.1%) patients treated with entecavir and 10355 (2.8%) patients treated with lamivudine. Among the 28 patients with confirmed HBsAg loss, 27 (96%) achieved HBV DNA <300 copiesmL, and 27 (96%) achieved confirmed HBeAg loss. All entecavir recipients with HBsAg loss had HBV DNA <300 copiesmL. Caucasian patients, and those infected with HBV genotype A or D, were significantly more likely to lose HBsAg. This retrospective analysis of data from a randomized, global phase three trial shows that confirmed loss of HBsAg occurred in 5% of nucleoside-naïve HBeAg-positive patients treated with entecavir, and that HBsAg loss is associated with sustained off-treatment suppression of HBV DNA. © 2009 Blackwell Publishing Ltd.
Persistent Identifierhttp://hdl.handle.net/10722/77360
ISSN
2015 Impact Factor: 4.179
2015 SCImago Journal Rankings: 1.815
ISI Accession Number ID
Funding AgencyGrant Number
Bristol-Myers Squibb Company
Funding Information:

This study was supported by funding from Bristol-Myers Squibb Company.

References

 

DC FieldValueLanguage
dc.contributor.authorGish, RGen_HK
dc.contributor.authorChang, TTen_HK
dc.contributor.authorLai, CLen_HK
dc.contributor.authorDe Man, Ren_HK
dc.contributor.authorGadano, Aen_HK
dc.contributor.authorPoordad, Fen_HK
dc.contributor.authorYang, Jen_HK
dc.contributor.authorBrettSmith, Hen_HK
dc.contributor.authorTamez, Ren_HK
dc.date.accessioned2010-09-06T07:31:04Z-
dc.date.available2010-09-06T07:31:04Z-
dc.date.issued2010en_HK
dc.identifier.citationJournal Of Viral Hepatitis, 2010, v. 17 n. 1, p. 16-22en_HK
dc.identifier.issn1352-0504en_HK
dc.identifier.urihttp://hdl.handle.net/10722/77360-
dc.description.abstractThis retrospective analysis was conducted to describe the characteristics of nucleoside-naïve hepatitis B e antigen (HBeAg)-positive patients with chronic hepatitis B, who achieved hepatitis B surface antigen (HBsAg) loss during entecavir or lamivudine therapy. HBeAg-positive adults with chronic hepatitis B, elevated serum alanine aminotransferase, and compensated liver disease were randomized to double-blind treatment for up to 96 weeks with entecavir 0.5 mgday or lamivudine 100 mgday. HBsAg and hepatitis B virus (HBV) DNA were measured at regular intervals during and off-treatment follow-up. Through a maximum duration of 96 weeks on-treatment and 24 weeks off-treatment, HBsAg loss was confirmed in 18354 (5.1%) patients treated with entecavir and 10355 (2.8%) patients treated with lamivudine. Among the 28 patients with confirmed HBsAg loss, 27 (96%) achieved HBV DNA <300 copiesmL, and 27 (96%) achieved confirmed HBeAg loss. All entecavir recipients with HBsAg loss had HBV DNA <300 copiesmL. Caucasian patients, and those infected with HBV genotype A or D, were significantly more likely to lose HBsAg. This retrospective analysis of data from a randomized, global phase three trial shows that confirmed loss of HBsAg occurred in 5% of nucleoside-naïve HBeAg-positive patients treated with entecavir, and that HBsAg loss is associated with sustained off-treatment suppression of HBV DNA. © 2009 Blackwell Publishing Ltd.en_HK
dc.languageengen_HK
dc.publisherBlackwell Publishing Ltd.en_HK
dc.relation.ispartofJournal of Viral Hepatitisen_HK
dc.rightsJournal of Viral Hepatitis. Copyright © Blackwell Publishing Ltd.en_HK
dc.subjectEntecaviren_HK
dc.subjectHepatitisen_HK
dc.subjectHepatitis B surface antigenen_HK
dc.subjectHepatitis B virusen_HK
dc.titleLoss of HBsAg antigen during treatment with entecavir or lamivudine in nucleoside-naïve HBeAg-positive patients with chronic hepatitis Ben_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1352-0504&volume=&spage=&epage=&date=2009&atitle=Loss+of+HBsAg+antigen+during+treatment+with+entecavir+or+lamivudine+in+nucleoside-naive+HBeAg-positive+patients+with+chronic+hepatitis+B*en_HK
dc.identifier.emailLai, CL:hrmelcl@hku.hken_HK
dc.identifier.authorityLai, CL=rp00314en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1111/j.1365-2893.2009.01146.xen_HK
dc.identifier.pmid19622117-
dc.identifier.scopuseid_2-s2.0-72949113706en_HK
dc.identifier.hkuros161274en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-72949113706&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume17en_HK
dc.identifier.issue1en_HK
dc.identifier.spage16en_HK
dc.identifier.epage22en_HK
dc.identifier.isiWOS:000273731700002-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridGish, RG=7007037133en_HK
dc.identifier.scopusauthoridChang, TT=7404725147en_HK
dc.identifier.scopusauthoridLai, CL=7403086396en_HK
dc.identifier.scopusauthoridDe Man, R=7006113112en_HK
dc.identifier.scopusauthoridGadano, A=7003915650en_HK
dc.identifier.scopusauthoridPoordad, F=6603753291en_HK
dc.identifier.scopusauthoridYang, J=15039392900en_HK
dc.identifier.scopusauthoridBrettSmith, H=7801442680en_HK
dc.identifier.scopusauthoridTamez, R=25634823500en_HK
dc.identifier.citeulike6466661-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats